- Home
- SUPN vs ARCB Comparison
SUPN vs ARCB Comparison
Compare SUPN & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- ARCB
- Stock Information
- Founded
- SUPN 2005
- ARCB 1923
- Country
- SUPN United States
- ARCB United States
- Employees
- SUPN N/A
- ARCB N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- ARCB Trucking Freight/Courier Services
- Sector
- SUPN Health Care
- ARCB Industrials
- Exchange
- SUPN Nasdaq
- ARCB Nasdaq
- Market Cap
- SUPN 1.7B
- ARCB 1.4B
- IPO Year
- SUPN 2012
- ARCB N/A
- Fundamental
- Price
- SUPN $30.76
- ARCB $60.99
- Analyst Decision
- SUPN Hold
- ARCB Buy
- Analyst Count
- SUPN 2
- ARCB 13
- Target Price
- SUPN $36.00
- ARCB $101.75
- AVG Volume (30 Days)
- SUPN 647.0K
- ARCB 422.6K
- Earning Date
- SUPN 05-07-2025
- ARCB 04-29-2025
- Dividend Yield
- SUPN N/A
- ARCB 0.79%
- EPS Growth
- SUPN 6500.00
- ARCB N/A
- EPS
- SUPN 1.32
- ARCB 7.31
- Revenue
- SUPN $661,817,000.00
- ARCB $4,179,019,000.00
- Revenue This Year
- SUPN N/A
- ARCB $3.83
- Revenue Next Year
- SUPN $9.32
- ARCB $7.17
- P/E Ratio
- SUPN $23.30
- ARCB $8.38
- Revenue Growth
- SUPN 8.94
- ARCB N/A
- 52 Week Low
- SUPN $25.53
- ARCB $57.80
- 52 Week High
- SUPN $40.28
- ARCB $150.29
- Technical
- Relative Strength Index (RSI)
- SUPN 40.39
- ARCB 38.75
- Support Level
- SUPN $29.77
- ARCB $57.38
- Resistance Level
- SUPN $34.26
- ARCB $63.92
- Average True Range (ATR)
- SUPN 1.51
- ARCB 5.05
- MACD
- SUPN -0.04
- ARCB -0.16
- Stochastic Oscillator
- SUPN 22.05
- ARCB 22.92
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About ARCB ArcBest Corporation
ArcBest Corp is engaged in logistics operations. The company operates in two operating segments, The Asset-Based segment includes the results of operations of ABF Freight System, Inc. and certain other subsidiaries. The segment operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed LTL services. The services including freight transportation related to managed transportation solutions and other services. The Asset-Light segment includes the results of operations of the Company's service offerings in truckload, ground expedite, dedicated, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.